Innovation Pharmaceuticals (Innovation Pharmaceuticals) Interest Expense : $-0.06 Mil (TTM As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Innovation Pharmaceuticals's interest expense for the three months ended in Sep. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Innovation Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $ -0.80 Mil. Innovation Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $ -0.01 Mil. Innovation Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innovation Pharmaceuticals Interest Expense Historical Data

The historical data trend for Innovation Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals Interest Expense Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-2.20

-0.26

-4.86

-0.12

-0.06

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.01	-0.02	-0.01	-0.01

Innovation Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

Innovation Pharmaceuticals (OTCPK:IPIX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innovation Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-0.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $0.00 Mil.

Innovation Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Innovation Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website

http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Executives

Arthur Peter Bertolino	officer: Pres. & Chief Medical Officer	C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness	officer: Vice President	100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin	director	C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor	director	17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter	director	7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich	director, 10 percent owner, officer: Chief Financial Officer	C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon	director, 10 percent owner, officer: President-Chief Scient.Officer	10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans	director, officer: Chief Executive Officer	17 IRVING PLACE, PELHAM NY 10803